Furthermore, PROTAC 8 reduced AR levels in prostate cancer-resistant cells LNCaP (approximately 3.5-fold at 10 μM), while AR was substantially increased in cells treated with enzalutamide (approximately 17.5-fold at 10 μM). The gene discussed is AR; the disease is prostate cancer.